# Integer Holdings Corp: Form 10-Q for the period ended Mar 31, 2023

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2023-04-27
- Accepted by EDGAR: Apr 27, 2023, 17:15 ET
- Period: 2023-03-31
- Accession: 0001114483-23-000016
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448323000016/itgr-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448323000016/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $378.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $282.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $96.7m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2023-01-01 to 2023-03-31 | $41.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $34.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $17.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $2.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $13.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.39 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.39 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 33,575,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | $6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $24.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $40.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $629.0m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $2.87bn | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $225.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $1.46bn | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $992.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-03-31 | $10.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2023-03-31 | $1.42bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 37,615 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2022. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this Form 10-Q and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- recovery from the COVID-19 global pandemic;
- future sales, expenses, and profitability; customer demand; supplier performance (including delivery delays); costs (including wages, staffing levels and freight); future development and expected growth of our business and industry, including expansion of our manufacturing capacity;
- our ability to execute our business model and our business strategy, including completion and integration of current or future acquisition targets;
- having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
- projected capital spending.

You can identify forward-looking statements by terminology such as “outlook,” “projected,” “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this Form 10-Q.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC and include the following:

- operational risks, such as the duration, scope and impact of the COVID-19 pandemic, including the evolving health, economic, social and governmental environments and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our reliance on third party suppliers for raw materials, key products and subcomponents; our ability to attract, train and retain a sufficient number of qualified associates; the potential for harm to our reputation caused by quality problems related to our products; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; interruptions in our manufacturing operations; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; our dependence upon our senior management team and technical personnel; and global climate change and the emphasis on ESG matters by various stakeholders;
- strategic risks, such as the intense competition we face and our ability to successfully market our products; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
- financial risks, such as our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets; and

\- 28 -

- legal and compliance risks, such as regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability and the cost to comply with environmental regulations; our ability to comply with customer-driven policies and third party standards or certification requirements; our ability to obtain necessary licenses for new technologies; legal and regulatory risks from our international operations; and the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and
- other risks and uncertainties that arise from time to time.

Except as may be required by applicable law, the Company assumes no obligation to update forward-looking statements in this Form 10-Q whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line. For more information on our segments, please refer to Note 14 “Segment Information” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report.

The first quarters of 2023 and 2022 ended on March 31 and April 1, respectively, and consisted of 90 days and 91 days, respectively.

### Impact of Global Events

Global economic challenges, including the impact of the war in Ukraine, the COVID-19 pandemic, severe and sustained inflation, a rising interest rate environment, fluctuations in global currencies, and supply chain disruptions may continue to cause economic uncertainty and volatility. The impact of these issues on our business will vary by geographic market and product line, but specific impacts to our business include increased borrowing costs, labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. We monitor economic conditions closely. In response to reductions in revenue, we can take actions to align our cost structure with changes in demand and manage our working capital. However, there can be no assurance as to the effectiveness of our efforts to mitigate any impact of the current and future adverse economic conditions and other developments.

### Business Acquisitions

On April 6, 2022, we acquired 100% of the equity interests of Connemara Biomedical Holdings Teoranta, including its operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively “Aran”). A recognized leader in proprietary medical textiles, high precision biomaterial coverings and coatings as well as advanced metal and polymer braiding, Aran delivers development and manufacturing solutions for implantable medical devices. Consistent with our strategy, the combination with Aran further increases our ability to offer complete solutions for complex delivery and therapeutic devices in high growth cardiovascular markets such as structural heart, neurovascular, peripheral vascular, and endovascular as well as general surgery.

Refer to Note 2 “Business Acquisitions” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these acquisitions.

\- 29 -

### Financial Overview

Net income for the first quarter of 2023 was $13.1 million, or $0.39 per diluted share, compared to $11.4 million, or $0.34 per diluted share, for the first quarter of 2022. These variances are primarily the result of the following:

- Sales for the first quarter of 2023 increased $67.9 million when compared to the same period in 2022 primarily from the continued product demand recovery from the impacts of the COVID-19 pandemic.
- Gross profit for the first quarter of 2023 increased $15.2 million, primarily from higher sales volume, partially offset by incremental labor and supply chain costs.
- Operating expenses for the first quarter of 2023 increased $3.5 million when compared to the same period in 2022, primarily due to higher SG&A and RD&E costs, partially offset by lower acquisition and integration costs. Operating expenses as a percentage of sales improved to 16.5% for the first quarter of 2023 compared to 19.0% or the first quarter of 2022.
- Interest expense for the first quarter of 2023 increased $11.3 million compared to the same period in 2022, due to increased interest rates, higher average debt outstanding and $4.4 million of losses from extinguishment of debt.
- During the first quarters of 2023 and 2022, we recognized losses on equity investments of $0.2 million and $2.4 million, respectively. Gains and losses on equity investments are generally unpredictable in nature.
- Other loss, net for the first quarter of 2023 was $0.8 million compared to $0.2 million for the first quarter of 2022, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
- We recorded provisions for income taxes for the first quarters of 2023 and 2022 of $2.9 million and $2.6 million, respectively. The change in income tax expense was primarily due to relative changes in pre-tax income and the impact of discrete tax items.

\- 30 -

### Our Financial Results

The following table presents selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share).

| Medical Sales: | Three Months Ended March 31, 2023 | April 1, 2022 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | 191,203 | $159,037 | $32,166 | 20.2% |
| Cardiac Rhythm Management & Neuromodulation | 145,139 | 123,324 | 21,815 | 17.7% |
| Advanced Surgical, Orthopedics & Portable Medical | 27,924 | 19,666 | 8,258 | 42.0% |
| Total Medical Sales | 364,266 | 302,027 | 62,239 | 20.6% |
| **Non-Medical** | 14,519 | 8,885 | 5,634 | 63.4% |
| Total sales | 378,785 | 310,912 | 67,873 | 21.8% |
| Cost of sales | 282,112 | 229,437 | 52,675 | 23.0% |
| Gross profit | 96,673 | 81,475 | 15,198 | 18.7% |
| Gross profit as a % of sales | 25.5% | 26.2% |  |  |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative (“SG&A”) | 41,886 | 39,560 | 2,326 | 5.9% |
| SG&A as a % of sales | 11.1% | 12.7% |  |  |
| Research, development and engineering (“RD&E”) | 19,092 | 16,083 | 3,009 | 18.7% |
| RD&E as a % of sales | 5.0% | 5.2% |  |  |
| Restructuring and other charges | 1,529 | 3,335 | (1,806) | (54.2)% |
| Total operating expenses | 62,507 | 58,978 | 3,529 | 6.0% |
| Operating income | 34,166 | 22,497 | 11,669 | 51.9% |
| Operating expense as a % of sales | 16.5% | 19.0% |  |  |
| Operating income as a % of sales | 9.0% | 7.2% |  |  |
| Interest expense | 17,254 | 5,968 | 11,286 | 189.1% |
| Loss on equity investments | 155 | 2,404 | (2,249) | (93.6)% |
| Other loss, net | 760 | 177 | 583 | NM |
| Income before taxes | 15,997 | 13,948 | 2,049 | 14.7% |
| Provision for income taxes | 2,932 | 2,581 | 351 | 13.6% |
| Effective tax rate | 18.3% | 18.5% |  |  |
| Net income | $13,065 | $11,367 | $1,698 | 14.9% |
| Net income as a % of sales | 3.4% | 3.7% |  |  |
| Diluted earnings per share | $0.39 | $0.34 | $0.05 | 14.7% |

NM Calculated amount not meaningful

\- 31 -

### Product Line Sales

For the first quarter of 2023, Cardio & Vascular (“C&V”) sales increased $32.2 million, or 20%, versus the comparable 2022 period. The increase in C&V sales was driven by strong demand across all markets and key products, such as guidewires, new product ramps in electrophysiology, as well as strong performance from the Oscor and Aran acquisitions. Foreign currency exchange rate fluctuations decreased C&V sales for the first quarter of 2023 by $0.7 million in comparison to the 2022 period, primarily due to U.S. dollar fluctuations relative to the Euro.

For the first quarter of 2023, Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales increased $21.8 million, or 18%, versus the comparable 2022 period, driven by strong demand, including double-digit growth from emerging customers with PMA (premarket approval) products. Foreign currency exchange rate fluctuations did not have a material impact on CRM&N sales during the first quarter of 2023 in comparison to 2022.

Advanced Surgical, Orthopedic & Portable Medical (“AS&O”) sales for the first quarter of 2023 increased $8.3 million, or 42%, versus the comparable 2022 period, primarily due to increased price and demand as a result of the execution of the multi-year Portable Medical exit announced in 2022, partially offset by a single-digit decline in Advanced Surgical and Orthopedics. Foreign currency exchange rate fluctuations did not have a material impact on AS&O sales during the first quarter of 2023 in comparison to 2022.

For the first quarter of 2023, Non-Medical sales increased $5.6 million, or 63%, versus the comparable 2022 period, driven by strong demand across all market segments and continued supplier delivery recovery. Foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the first quarter of 2023 in comparison to 2022.

### Gross Profit

|  | Three Months Ended March 31, 2023 | April 1, 2022 |
| --- | ---: | ---: |
| Gross profit (in thousands) | $96,673 | $81,475 |
| Gross margin | 25.5% | 26.2% |

Gross margin for the first quarter of 2023 decreased 70 basis points compared to the comparable 2022 period, primarily driven by incremental labor and supply chain costs related to manufacturing efficiency headwinds from supply chain volatility.

\- 32 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Three Months Ended March 31, 2023 | April 1, 2022 | Change |
| --- | ---: | ---: | ---: |
| Compensation and benefits | $21,589 | $21,846 | $(257) |
| Amortization expense(a) | 9,137 | 8,027 | 1,110 |
| Professional fees(b) | 3,471 | 3,173 | 298 |
| Contract services(c) | 2,832 | 2,251 | 581 |
| All other SG&A(d) | 4,857 | 4,263 | 594 |
| Net increase in SG&A expenses | $41,886 | $39,560 | $2,326 |

(a) Amortization expense increased during the first quarter of 2023 compared to the same period of 2022 due to amortization of intangible assets from the Aran acquisition, which was acquired in the second quarter of 2022.

(b) Professional fees increased during the first quarter of 2023 primarily due to inclusion of the operations of Aran.

(c) Contract services expense increased during the first quarter of 2023 compared to the same period of 2022 primarily due to higher software costs from information technology enhancements.

(d) The net increase in all other SG&A for the first quarter of 2023 compared to the same period of 2022 is primarily attributable to higher supplies and travel costs partially offset by lower depreciation and insurance.

### RD&E

RD&E expense for the first quarter of 2023 was $19.1 million, compared to $16.1 million for the first quarter of 2022. The increase in RD&E expenses for 2023 compared to 2022 was primarily due to investments made to support long-term revenue growth, the timing of program milestone achievements for customer funded programs, and incremental expense due to the Aran Acquisition. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

\- 33 -

### Restructuring and Other Charges

We continuously evaluate our business and identify opportunities to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs. To realize the benefits associated with these opportunities, we undertake restructuring-type activities to transform our business. We incur costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative. Restructuring charges include exit and disposal costs from these activities and restructuring-related charges are costs directly related to the restructuring initiatives. In addition, from time to time, we incur costs associated with acquiring and integrating businesses, and certain other general expenses, including asset impairments.

Restructuring and other charges comprise the following (in thousands):

|  | Three Months Ended March 31, 2023 | April 1, 2022 |
| --- | ---: | ---: |
| Restructuring charges(a) | $1,064 | $1,103 |
| Acquisition and integration costs(b) | 382 | 1,936 |
| Other general expenses(c) | 83 | 296 |
| Total restructuring and other charges | $1,529 | $3,335 |

(a) Restructuring charges for the first three months of 2023 and 2022 primarily consist of termination benefits associated with our operational excellence and strategic reorganization and alignment initiatives.

(b) Amounts include expenses related to the purchase of certain assets and liabilities from business acquisitions. Acquisition and integration costs for the three months ended March 31, 2023 and April 1, 2022 include a benefit of $0.3 million and expense of $0.1 million, respectively, to adjust the fair value of acquisition-related contingent consideration liabilities. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. Amounts for 2022 primarily include expenses related to the Aran and Oscor acquisitions.

(c) Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies.

Refer to Note 8 “Restructuring and Other Charges” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding these initiatives.

\- 34 -

### Interest Expense

Information relating to our interest expense is as follows (dollars in thousands):

|  | Three Months Ended March 31, 2023 Amount | Rate | April 1, 2022 Amount | Rate | Change Amount | Rate (bp) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Contractual interest expense | $12,562 | 5.06% | $4,647 | 2.21% | $7,915 | 285 |
| (Gain) loss on interest rate swap | (587) | (0.24) | 768 | 0.37 | (1,355) | (61) |
| Amortization of deferred debt issuance costs and original issue discount | 756 | 0.38 | 481 | 0.25 | 275 | 13 |
| Losses from extinguishment of debt | 4,393 | 1.79 | — | — | 4,393 | 179 |
| Interest expense on borrowings | 17,124 | 6.99% | 5,896 | 2.83% | 11,228 | 416 |
| Other interest expense | 130 |  | 72 |  | 58 |  |
| Total interest expense | $17,254 |  | $5,968 |  | $11,286 |  |

During 2023, contractual interest expense has increased due to higher average debt outstanding combined with increasing applicable interest rates. The higher average debt balance outstanding is the result of borrowings to fund the Aran acquisition, while interest rates have continued to climb due to increases in overall market rates.

Other components of interest expense on borrowings include gains and losses on interest rate swaps and non-cash amortization and write-off (losses from extinguishment of debt) of deferred debt issuance costs and original issue discount. Interest rate swap includes realized (gains) losses on our interest rate swap contract which fluctuate depending on the spread between the rate swap contract fixed rate and senior secured credit facility floating rate. Compared to the same periods in 2022, amortization of deferred debt issuance costs and original issue discount increased as a result of higher unamortized balances related to new debt. The losses from extinguishment of debt during the first three months of 2023 were related to prepayments of portions of the Term Loan A facility and full repayment of our Term Loan B facility in connection with the issuance of the convertible notes. We had no losses from extinguishment of debt during the first three months of 2022.

As of March 31, 2023 and December 31, 2022, approximately 59% and 11%, respectively, of our principal amount of debt are fixed rate borrowings or have been converted to fixed-rate borrowings with an interest rate swap. During February 2023, we strategically replaced about half of our variable rate debt with fixed rate debt through the issuance of the 2028 Notes at a fixed rate of 2.125% and paying down our highest rate variable debt, the Term Loan B facility, and a portion of our Revolving Credit Facility. These transactions are expected to reduce borrowing costs and result in a more balanced mix of fixed and floating rates to help protect against interest rate exposure. We may enter into interest rate swap agreements in order to reduce our exposure to fluctuations in floating rates. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our interest rate swap agreement.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

### Loss on Equity Investments

During the first quarters of 2023 and 2022, we recognized losses on equity investments of $0.2 million and $2.4 million, respectively. The amounts for both 2023 and 2022 relate to our share of equity method investee losses including unrealized depreciation of the underlying interests of the investee. As of March 31, 2023 and December 31, 2022, the carrying value of our equity investments was $13.7 million and $13.9 million, respectively. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

### Other Loss, Net

Other loss, net for the first quarter of 2023 was $0.8 million compared to $0.2 million for the first quarter of 2022. Other loss, net primarily includes gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, Dominican peso, or Israeli shekel.

\- 35 -

The impact of exchange rates on transactions denominated in foreign currencies included in Other loss, net for the first quarters of 2023 and 2022 were net losses of $0.8 million and $0.1 million, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in exchange rates could have a significant impact, positive or negative, on our financial results in the future.

### Provision for Income Taxes

We recognized income tax expense of $2.9 million for the first quarter of 2023 on $16.0 million of income before taxes (effective tax rate of 18.3%), compared to an income tax expense of $2.6 million on $13.9 million of income before taxes (effective tax rate of 18.5%) for the same period of 2022. Income tax expense for the first quarters of 2023 and 2022 included discrete tax expense of $0.1 million and $0.5 million, respectively.

Our effective tax rate for 2023 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of Federal Tax Credits (including R&D credits and Foreign tax credits), stock-based compensation windfalls or shortfalls, and the impact of earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate. These benefits are partially offset by the impact of U.S taxes on foreign earnings, including the GILTI provision which requires us to include foreign subsidiary earnings in excess of a deemed return on a foreign subsidiary’s tangible assets in our U.S. income tax return. The U.S. tax on foreign earnings is reflected net of a statutory deduction of 50% of the GILTI inclusion (subject to limitations based on U.S. taxable income, if any) and net of FDII that provides a 37.5% deduction to domestic companies for certain foreign sales and services income. The primary foreign jurisdictions in which we operate and the statutory tax rate for each respective jurisdiction include Switzerland (22%), Mexico (30%), Uruguay (25%), Ireland (12.5%) and Malaysia (24%). We currently have a tax holiday in Malaysia through April 2023, provided certain conditions continue to be met. In addition, we acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor, and are operating under a free trade zone agreement in the Dominican Republic through March 2034.

There is a potential for volatility of our effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, business acquisitions, settlements with taxing authorities, changes in tax rates, and foreign currency exchange rate fluctuations. In addition, we continue to explore tax planning opportunities that may have a material impact on our effective tax rate.

### Liquidity and Capital Resources

### Sources of Liquidity

*(dollars in thousands)*

|  | March 31, 2023 | December 31, 2022 |
| --- | ---: | ---: |
| Cash and cash equivalents | $40,604 | $24,272 |
| Working capital | $403,514 | $334,546 |
| Current ratio | 2.79 | 2.50 |

Cash and cash equivalents at March 31, 2023 increased by $16.3 million from December 31, 2022, primarily as a result of cash generated by operating activities and proceeds from net borrowings on long-term debt, partially offset by purchases of property, plant and equipment.

Working capital increased by $69.0 million from December 31, 2022, primarily from positive working capital fluctuations in cash, accounts receivable and inventory, which were partially offset by increases in accounts payable. During the first three months of 2022, accounts receivable increased mainly from an increase in sales volume and timing of customer receipts while inventory increased to support higher product demand, sales volume and material stock levels to protect availability of critical components. Accounts payable increased mainly from higher sequential inventory purchases and the timing of supplier payments.

At March 31, 2023, $24.8 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

\- 36 -

As of March 31, 2023, our capital structure consisted of $1,002.5 million of debt, net of deferred debt issuance costs and unamortized discounts and 33 million shares of common stock outstanding. As of March 31, 2023, we had access to $377.5 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit, and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of March 31, 2023, our contractual debt service obligations for the remainder of 2023, consisting of principal and interest on our outstanding debt, were estimated to be approximately $40 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

### Credit Facilities and Convertible Notes

As of March 31, 2023, we had Senior Secured Credit Facilities that consist of a $500 million Revolving Credit Facility, with an outstanding principal balance of $119 million, and a TLA Facility with an outstanding principal balance of $400 million. The Revolving Credit Facility and TLA Facility mature on February 15, 2028. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature.

During the first quarter of 2023, we issued $500 million aggregate principal amount of notes. The 2028 Notes mature on February 15, 2028 and bear interest at a fixed rate of 2.125% per annum. The total net proceeds from the issuance of the 2028 Notes, after deducting initial purchasers' discounts and commissions and debt issuance costs, were approximately $485 million. We used the net proceeds from the issuance of the 2028 Notes to settle in full principal and interest due of $336.1 million under the TLB Facility, pay down principal and interest due of $113.9 million under the Revolving Credit Facility, to pay related fees and expenses, and to pay the cost of the capped calls related to the issuance of our 2028 Notes.

The Revolving Credit Facility and TLA Facility contain covenants requiring that we maintain (i) a Total Net Leverage Ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following certain qualified acquisitions) and (ii) an interest coverage ratio of at least 2.50:1.00. As of March 31, 2023, we were in compliance with these financial covenants. As of March 31, 2023, our Total Net Leverage Ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.1 to 1.0. For the twelve month period ended March 31, 2023, our interest coverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 7.7 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

\- 37 -

### Summary of Cash Flow

*(in thousands)*

| Cash provided by (used in): | Three Months Ended March 31, 2023 | April 1, 2022 |
| --- | ---: | ---: |
| Operating activities | $6,188 | $18,161 |
| Investing activities | (24,694) | (10,398) |
| Financing activities | 33,116 | (1,028) |
| Effect of foreign currency exchange rates on cash and cash equivalents | 1,722 | 1,048 |
| Net change in cash and cash equivalents | $16,332 | $7,783 |

***Operating Activities –*** During the first three months of 2023, we generated cash from operations of $6.2 million, compared to $18.2 million for the first three months of 2022. The decrease of $12.0 million was the result of a $15.9 million decrease in cash flow provided by changes in operating assets and liabilities, partially offset by a $3.9 million increase in net income adjusted for non-cash items such as depreciation and amortization.

The increase in net income adjusted for non-cash items such as depreciation and amortization is primarily from higher sales volume partially offset by higher interest expense. The decrease associated with changes in operating assets and liabilities is primarily related to higher accounts receivable and contract asset growth in the current period partially offset by less inventory growth.

***Investing Activities –*** The $14.3 million increase in net cash used in investing activities was primarily attributable to increased purchases of property, plant and equipment of $24.7 million in the first three months of 2023, compared to $10.9 million in the same period last year.

***Financing Activities –*** Net cash provided by financing activities for the first three months of 2023, was $33.1 million compared to $1.0 million used in financing activities for the first three months of 2022. The cash provided by financing activities for the first three months of 2023 was primarily related to the issuance of our 2028 Notes of $486.3 million, which was partially offset by $335.6 million in full repayment of our term loan B facility, $55.3 million in repayments of our term loan A facility, $23.8 million of net payments on our Revolving Credit Facility and $35.0 million of capped call purchases related to the issuance of our 2028 Notes.

### Off-Balance Sheet Arrangements

We do not currently have off balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our Condensed Consolidated Financial Statements.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the FASB, SEC, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022.

\- 38 -

## Market risk

As filed, 542 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,414 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of March 31, 2023. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of March 31, 2023, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

\- 39 -

## Risk factors

As filed, 171 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Filed Apr 27, 2023.
Source: SEC EDGAR, the filing index for accession 0001114483-23-000016. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
